SCHEMBL7735182

SCHEMBL7735182

Nc1c(O)cc(Cl)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
HSD17B10 Q99714 4/20 0.41
TSHR P16473 3/20 0.41
HPGD P15428 2/20 0.41
CA1 P00915 7/20 0.41
CA2 P00918 7/20 0.41
CA9 Q16790 5/20 0.41
ERN1 O75460 1/20 0.41
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CA3 P07451 1/20 0.38
CYP3A4 P08684 3/20 0.36
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MCL1 Q07820 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639812 0.82 GAA (0.58) ALDH1A1TSHRCA1CA2CA9
SCHEMBL205669 0.75 GAA (0.43) ALDH1A1HSD17B10TSHRHPGDCA1
SCHEMBL264625 0.75 ERN1 (0.54) ALDH1A1HSD17B10TSHRHPGDCA1
SCHEMBL3314453 0.75 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRHPGDCA1
SCHEMBL2885441 0.75 TSHR (0.56) ALDH1A1HSD17B10TSHRHPGDCA1
SCHEMBL5681905 0.75 CYP3A4 (0.50) ALDH1A1TSHRHPGDCA1CA2
SCHEMBL3605101 0.75 CA1 (0.54) ALDH1A1HSD17B10TSHRCA1CA2
SCHEMBL31050390 0.75 CA1 (0.54) ALDH1A1HSD17B10TSHRCA1CA2
SCHEMBL23883715 0.71 TSHR (0.41) ALDH1A1HSD17B10TSHRHPGDCA1
SCHEMBL2427550 0.71 CYP3A4 (0.40) ALDH1A1TSHRCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240208991-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD (KR) 2024-06-27 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-20240109884-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD. (KR) 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116917292-A Novel compound and organic light emitting device comprising the same 株式会社LG化学 2023-10-20 CN disclosed
CN-116745302-A Novel compound and organic light emitting device comprising the same 株式会社LG化学 2023-09-12 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-3020718-A1 NOVEL PDE4 INHIBITOR Meiji Seika Pharma Co., Ltd. (JP) 2016-05-18 EP disclosed
CN-105431427-A Novel PDE4 inhibitor MEIJI SEIKA PHARMA CO LTD 2016-03-23 CN disclosed
EP-2970157-A2 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 Janssen Pharmaceutica, N.V. (BE) 2016-01-20 EP disclosed
WO-2014159061-A2 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2014-10-02 WO disclosed
US-20140275172-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 US disclosed
US-6372770-B1 TREATING A MAMMAL SUFFERING FROM A DISEASE STATE SELECTED FROM THE GROUP CONSISTING OF ASTHMA, ALLERGIES, INFLAMMATION, DEPRESSION, DEMENTIA, ATOPIC DISEASES, RHINITIS AND DISEASE STATES ASSOCIATED WITH ABNORMALLY HIGH PHYSIOLOGICAL LEVELS OF EURO-CELTIQUE, S.A. 2002-04-16 US disclosed
EP-0785927-A4 NOVEL BENZOXAZOLES EURO CELTIQUE SA (LU) 1997-12-29 EP disclosed
US-5665737-A PHOSPHODIESTERASE INHIBITORS EURO-CELTIQUE, S.A. (LU) 1997-09-09 US disclosed
EP-0785927-A1 NOVEL BENZOXAZOLES Euroceltique S.A. (LU) 1997-07-30 EP disclosed
WO-1996011917-A1 NOVEL BENZOXAZOLES EURO-CELTIQUE, S.A. (LU) 1996-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208991-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CCNL2, UBE2L3 ALDH1A1 1216/4885HSD17B10 2086/4885TSHR 1524/4885
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 ALDH1A1 653/4885HSD17B10 1464/4885TSHR 2377/4885
US-20240109884-A1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CCND1, CRY2 ALDH1A1 88/4885HSD17B10 1083/4885TSHR 3423/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 ALDH1A1 653/4885HSD17B10 1464/4885TSHR 2377/4885
US-20140275172-A1 BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 GPR119, GPR180, GPR55 ALDH1A1 2452/4885HSD17B10 568/4885TSHR 921/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH ALDH1A1 3178/4885HSD17B10 2859/4885TSHR 437/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 ALDH1A1 3094/4885HSD17B10 1492/4885TSHR 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.